Down -10.33% in 4 Weeks, Here's Why You Should You Buy the Dip in Sarepta Therapeutics (SRPT)Zacks Investment Research • 08/09/24
Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate DevelopmentsBusiness Wire • 08/07/24
7 Best Stocks For Magnificent Earnings Growth Next Year. See Who's New.Investors Business Daily • 07/30/24
Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying OpportunitySeeking Alpha • 07/24/24
Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 38.04%: Here's is How to TradeZacks Investment Research • 07/19/24
What Makes Sarepta Therapeutics (SRPT) a Strong Momentum Stock: Buy Now?Zacks Investment Research • 07/16/24
Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?The Motley Fool • 07/04/24
Sarepta Therapeutics (SRPT) Soars 30.1%: Is Further Upside Left in the Stock?Zacks Investment Research • 06/24/24
Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid UncertaintyBenzinga • 06/21/24
Wall Street Beats to Host Conference Call with Sarepta CEO on Ground-Breaking Expanded Label ApprovalBusiness Wire • 06/21/24
Sarepta's Expanded FDA Approval For Elevidys Potentially Shaping Future FDA Reviews, Analyst SaysBenzinga • 06/21/24